login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

First successful below-the-knee procedures with the Proteus device performed in the USA


Friday, 13 Jul 2012 13:47
Proteus
Proteus

Angioslide, a provider of embolic capture angioplasty solutions, has announced the successful deployment of a 3X100mm Proteus device for treating peripheral artery disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, USA. Accommodating a 0.014” guide-wire, the new device allows physician to perform a PTA revascularisation in BTK vessels while capturing and removing embolic particles. 


“With Proteus having been successfully used to treat lesions in the SFA (superficial femoral artery), I had the opportunity to deploy the device in BTK procedures,” said Prakash Makam, Community Hospital. “It is an effective, easy to use tool that provides an alternative for removal of embolic material, including micro particles, that could compromise downstream vasculature flow and perfusion to the foot. This is especially important when treating high-risk, diabetic and critical limb ischaemia patients.”

Angioslide’s proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention. Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity. When retrieved through the sheath, Proteus removes the captured material from the body.


“We are excited to provide a solution for capture and removal of embolic debris for below-the-knee intervention, where the clinical consequences of emboli are amplified by small vessel diameter,” said Lihu Avitov, CEO, Angioslide. “The current set of tools available on the market for BTK intervention are suboptimal, and we look forward to meeting this important clinical need. With the successful completion of our first cases in the USA, we will introduce our product to a wider number of centers.”


According to a company release, the Proteus is the first device of its kind to receive FDA clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE mark approval for lower limb use and is being marketed in selected regions in Europe.




Add New Comment

Related Items


Most popular


Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

New deep vein thrombosis guidelines: What you need to know
Thursday, 23 Oct 2014
Suresh Vedantham spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus ... New deep vein thrombosis guidelines: What you need to know

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Features


Stentoplasty: An “exciting frontier” in spinal augmentation
Thursday, 27 Nov 2014
Stentoplasty, or vertebral body stenting, represents the next step in the evolution of cement spinal augmentation where a stent is placed within the vertebral body followed by infusion of cement. Stentoplasty: An “exciting frontier” in spinal augmentation

CO2 angiography should be more widely used
Thursday, 27 Nov 2014
CO2 angiography can decrease both morbidity and mortality for patients, in certain clinical scenarios. For those driven by economics, the cost of 100cc of CO2 is approximately three cents. Its use is ... CO2 angiography should be more widely used

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions